Omeprazole Increases the Efficacy of Acyclovir Against Herpes Simplex Virus Type 1 and 2
In conclusion, proton pump inhibitors increase the anti-HSV activity of acyclovir and are candidates for antiviral therapies in combination with acyclovir, in particular for topical preparations for the treatment of immunocompromised individuals who are more likely to suffer from severe complications. (Source: Frontiers in Microbiology)
Source: Frontiers in Microbiology - December 2, 2019 Category: Microbiology Source Type: research
Phase 4 Study in Patients From Asia With Gastroesophageal Reflux Disease Treated With Dexlansoprazole.
Conclusions: In Asian patients with GERD, treatment with dexlansoprazole modified-release indicates a favorable efficacy and safety profile in relieving heartburn and acid regurgitation symptoms.
PMID: 31597230 [PubMed - as supplied by publisher] (Source: Journal of Neurogastroenterology and Motility)
Source: Journal of Neurogastroenterology and Motility - October 11, 2019 Category: Gastroenterology Tags: J Neurogastroenterol Motil Source Type: research
A Comparison Between Dexlansoprazole Modified Release & ndash;Based And Lansoprazole-Based Nonbismuth Quadruple (Concomitant) Therapy For First-Line Helicobacter pylori Eradication: A Prospective Randomized Trial [Corrigendum]
(Source: Infection and Drug Resistance)
Source: Infection and Drug Resistance - September 25, 2019 Category: Infectious Diseases Tags: Infection and Drug Resistance Source Type: research
A comparison between dexlansoprazole modified release & ndash;based and lansoprazole-based nonbismuth quadruple (concomitant) therapy for first-line Helicobacter pylori eradication: a prospective randomized trial
(Source: Infection and Drug Resistance)
Source: Infection and Drug Resistance - September 16, 2019 Category: Infectious Diseases Tags: Infection and Drug Resistance Source Type: research
In defense of four decades of esophageal function tests. reply to reaction to articles on high resolution manometry, the length of the lower esophageal sphincter and the diagnosis of gastroesophageal reflux disease
CONCLUSION: Recognizing the historical evolution of GERD management can help care providers to better understand therapeutic options for their patients, as well as focus on unmet needs that deserve further attention. PPIs are still the first choice therapy, with good evidence in favor of their efficacy, despite some safety concerns. However, as with any medical intervention, it is recommended to prescribe PPIs for patients with clear indication, using adequate dosing and monitoring for adverse events.RESUMO CONTEXTO: A doen ça do refluxo gastroesofágico (DRGE) é uma das doenças gastrointestinais mais prevalentes, re...
Source: Arquivos de Gastroenterologia - August 27, 2019 Category: Gastroenterology Source Type: research
Reaction to articles on high resolution manometry, the length of the lower esophageal sphincter and the diagnosis of gastroesophageal reflux disease
CONCLUSION: Recognizing the historical evolution of GERD management can help care providers to better understand therapeutic options for their patients, as well as focus on unmet needs that deserve further attention. PPIs are still the first choice therapy, with good evidence in favor of their efficacy, despite some safety concerns. However, as with any medical intervention, it is recommended to prescribe PPIs for patients with clear indication, using adequate dosing and monitoring for adverse events.RESUMO CONTEXTO: A doen ça do refluxo gastroesofágico (DRGE) é uma das doenças gastrointestinais mais prevalentes, re...
Source: Arquivos de Gastroenterologia - August 27, 2019 Category: Gastroenterology Source Type: research
Historical perspective of gastroesophageal reflux disease clinical treatment
CONCLUSION: Recognizing the historical evolution of GERD management can help care providers to better understand therapeutic options for their patients, as well as focus on unmet needs that deserve further attention. PPIs are still the first choice therapy, with good evidence in favor of their efficacy, despite some safety concerns. However, as with any medical intervention, it is recommended to prescribe PPIs for patients with clear indication, using adequate dosing and monitoring for adverse events.RESUMO CONTEXTO: A doen ça do refluxo gastroesofágico (DRGE) é uma das doenças gastrointestinais mais prevalentes, re...
Source: Arquivos de Gastroenterologia - August 27, 2019 Category: Gastroenterology Source Type: research
Pharmacokinetic/Pharmacodynamic Evaluation of Dexlansoprazole Infusion Injection Compared with Lansoprazole in Healthy Chinese Adults
ConclusionEvery 12 h intravenous dosing of dexlansoprazole up to 30 mg for 5 days was safe and well-tolerated in healthy Chinese subjects. Every 12 h dosing of dexlansoprazole 15 mg has a comparable effect of gastric acid inhibition as lansoprazole 30 mg q12h.Trial RegistrationClinicalTrials.gov ID NCT03120273. (Source: Clinical Drug Investigation)
Source: Clinical Drug Investigation - July 22, 2019 Category: Drugs & Pharmacology Source Type: research
Reply
We thank Dr Sugiyama for his comments on our recent publication of a randomized, double-blind, placebo-controlled trial that assessed skeletal effects of treatment with dexlansoprazole (60 mg/d) or esomeprazole (40 mg/d), 2 potent proton pump inhibitors (PPIs), in 115 healthy postmenopausal women.1 The finding that there was no clinically meaningful effect of PPI use on areal-bone mineral density, albeit at 26 weeks, in conjunction with no meaningful impact of PPIs on bone turnover, intestinal calcium absorption, or serum or urine mineral levels, led to our conclusion that neither dexlansoprazole or esomeprazole seem to ha...
Source: Gastroenterology - June 11, 2019 Category: Gastroenterology Authors: Jeri W. Nieves, Maria Claudia Perez, David C. Metz, Karen E. Hansen Tags: Correspondence Source Type: research
Dexlansoprazole is Effective in Relieving Heartburn during the Fasting Month of Ramadan
Conclusion: Dexlansoprazole is effective in the treatment of heartburn during Ramadan. Clinicaltrials.gov number: NCT03079050.Dig Dis (Source: Digestive Diseases)
Source: Digestive Diseases - January 13, 2019 Category: Gastroenterology Source Type: research
Dexlansoprazole and Esomeprazole Do Not Affect Bone Homeostasis in Healthy Postmenopausal Women
Epidemiological studies have associated proton pump inhibitor (PPI) therapy with osteoporotic fractures, but it is not clear if PPIs directly cause osteoporosis. We evaluated the effect of dexlansoprazole and esomeprazole on bone turnover, bone mineral density (BMD), true fractional calcium absorption (TFCA), serum and urine levels of minerals, and levels of parathyroid hormone (PTH) in healthy postmenopausal women. (Source: Gastroenterology)
Source: Gastroenterology - November 13, 2018 Category: Gastroenterology Authors: Karen E. Hansen, Jeri W. Nieves, Sai Nudurupati, David C. Metz, Maria Claudia Perez Source Type: research
Dual Delayed-Release Dexlansoprazole for Healing and Maintenance of Healed Erosive Esophagitis: A Safety Study in Adolescents
ConclusionsDexlansoprazole is safe and efficacious for healing EE and maintenance of healed EE in adolescents. (Source: Digestive Diseases and Sciences)
Source: Digestive Diseases and Sciences - November 2, 2018 Category: Gastroenterology Source Type: research
Potent Acid Suppression with PPIs and P-CABs: What ’s New?
AbstractPurpose of the reviewAcid suppression treatment has revolutionized the management of the acid-related disorders since the introduction of the H2-receptor antagonists (H2-RAs) and the proton pump inhibitors (PPIs). However, there has been increasing identification of needs for improvement in antisecretory therapy, especially in gastroesophageal reflux disease (GERD), the eradication ofHelicobacter pylori (H. pylori), protection from aspirin (ASA) and non-steroidal inflammatory drug (NSAID) injury and the management of upper gastrointestinal (UGI) bleeding. There have also been increasing publications addressing safe...
Source: Current Treatment Options in Gastroenterology - October 25, 2018 Category: Gastroenterology Source Type: research
Trends in concomitant clopidogrel and proton pump inhibitor treatment among ACS inpatients, 2000 –2016
ConclusionsFindings suggest that clinical practice recommendations made by the FDA were followed. Further research is needed to determine how changes in drug labels and the availability of new drugs may have influenced the observed trends. (Source: European Journal of Clinical Pharmacology)
Source: European Journal of Clinical Pharmacology - October 15, 2018 Category: Drugs & Pharmacology Source Type: research
Bioavailability of dexlansoprazole delayed-release capsule granules when administered via nasogastric tube or orally via syringe
(Source: Clinical and Experimental Gastroenterology)
Source: Clinical and Experimental Gastroenterology - October 4, 2018 Category: Gastroenterology Tags: Clinical and Experimental Gastroenterology Source Type: research
